Difference between revisions of "Bexarotene (Targretin)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
| Line 16: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 12/29/1999: Initial FDA approval "for the treatment of cutaneous manifestations of [[ | + | * 12/29/1999: Initial FDA approval "for the treatment of cutaneous manifestations of [[cutaneous T-cell lymphoma]] in patients who are refractory to at least one prior systemic therapy." |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' LGD1069 | ||
| + | *'''Brand names:''' Bexgratin, Targretin | ||
==References== | ==References== | ||
| Line 22: | Line 26: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Topical medications]] | [[Category:Topical medications]] | ||
Revision as of 15:23, 23 July 2018
General information
Class/mechanism: Retinoid, selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ), which allow them to function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. Exact mechanism of action in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.[1][2][3]
Route: PO, topical
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Bexarotene (Targretin) package insert pages 16-19[1]
- Bexarotene systemic (Targretin) patient drug information (Chemocare)[4]
- Bexarotene systemic (Targretin) patient drug information (UpToDate)[5]
- Bexarotene topical (Targretin) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 12/29/1999: Initial FDA approval "for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy."
Also known as
- Code name: LGD1069
- Brand names: Bexgratin, Targretin
References
- ↑ 1.0 1.1 1.2 Bexarotene (Targretin) package insert
- ↑ Bexarotene (Targretin) package insert (locally hosted backup)
- ↑ Targretin manufacturer's website
- ↑ Bexarotene systemic (Targretin) patient drug information (Chemocare)
- ↑ Bexarotene systemic (Targretin) patient drug information (UpToDate)
- ↑ Bexarotene topical (Targretin) patient drug information (UpToDate)